RxDoctor Payments DataLook up a doctor →

Stephen Tyring, MD

Dermatology · Webster, TXNPI 1245227263

Payments from drug & device makers

$14,124,467in general payments, 2019–2025

Across 4,348 payments — averaging $3248.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3.2M
  • E.r. Squibb & Sons, L.L.C.$1.8M
  • Janssen Research & Development, LLC$1.1M
  • Eli Lilly$929K
  • Pfizer$852K
  • Incyte Corporation$802K
  • plus $5.4M from 54 others
$282,664in research payments, 2019–2025

Across 170 payments — averaging $1662.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ichnos Glenmark Innovation Inc$164K
  • Glenmark Pharmaceuticals Inc., USA$78K
  • Sanofi US Services Inc.$18K
  • Novartis$7K
  • Eli Lilly$7K
  • Almirall LLC$3K
  • plus $5K from 3 others

What the payments were for

  • Consulting fees$149,58217%
  • Speaking & faculty fees$646,70274%
  • Travel & lodging$36,3214%
  • Food & beverage$46,4925%
  • Education$4550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)1,045$3,171,411
E.r. Squibb & Sons, L.L.C.112$1,838,468
Janssen Research & Development, LLC257$1,144,238
Eli Lilly62$929,209
Pfizer373$852,311
Incyte Corporation455$802,121
Amgen68$801,967
UCB SA27$685,208
Novartis134$679,705
Boehringer Ingelheim34$463,019
Sun Pharmaceutical Industries Inc.271$415,850
Sanofi US Services Inc.60$295,866
Kyowa Kirin Pharmaceutical Development, Inc34$276,502
LEO Pharma AS29$269,361
Bristol Myers Squibb16$166,333
Regeneron138$140,370
Aclaris Therapeutics, Inc.16$137,051
Galderma Laboratories, L.p.99$126,035
GSK70$108,977
Acrotech Biopharma Inc.20$94,196
Dermavant Sciences, Inc.193$85,858
Johnson & Johnson(2 entities)223$80,785
Janssen Scientific Affairs, LLC76$76,142
VYNE Pharmaceuticals Inc.49$68,961
UCB Biosciences Inc.2$61,267
Bausch Health US, LLC9$58,497
Argenx US, Inc.11$46,538
Genentech, Inc.11$40,643
Boehringer Ingelheim International GmbH27$35,072
Merck4$25,488
LEO Pharma Inc.64$22,964
Sanofi Pasteur Inc.5$16,144
Sanofi90$16,040
Regeneron Healthcare Solutions, Inc.65$14,157
Teva Pharmaceuticals USA, Inc.2$13,162
UCB, Inc.25$11,278
Dr.reddy's Laboratories,inc.5$11,198
Vanda Pharmaceuticals Inc.3$9,935
Almirall LLC23$7,306
Genentech USA, Inc.6$6,645
Kyowa Kirin, Inc.1$5,270
Boehringer Ingelheim Pharma GmbH & Co.kg26$5,225
Takeda Pharmaceuticals U.S.A., Inc.4$4,009
Merz North America, Inc.2$738
Journey Medical Corporation6$424
Mallinckrodt Hospital Products Inc.15$319
Arcutis Biotherapeutics, Inc.21$312
Verrica Pharmaceuticals Inc.3$247
Ortho Dermatologics, A Division Of Bausch Health US, LLC8$226
Lilly USA, LLC7$225
Strata Skin Sciences, Inc.8$220
Organon10$199
Revance Therapeutics, Inc.2$150
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$146
AstraZeneca1$108
Medimetriks Pharmaceuticals, Inc.4$81
Convatec Inc.2$71
Sanofi-aventis U.S. LLC3$48
Mayne Pharma Commercial LLC2$29
Biofrontera Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,124,467 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$180,799
Medicare patients
547
Services billed
3,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa28$558,521
RinvoqUpadacitinib38$382,289
Dupixent PenDupilumab62$261,028
Humira(Cf) PenAdalimumab21$253,998
OtezlaApremilast31$152,251
TremfyaGuselkumab11$145,057
OpzeluraRuxolitinib Phosphate14$27,585
Clobetasol Propionate226$10,029
Triamcinolone Acetonide341$5,652
Fluocinonide139$5,299
Ketoconazole280$4,838
Desonide53$4,678
Tacrolimus21$3,998
Doxycycline Hyclate134$3,112
ValacyclovirValacyclovir Hcl43$2,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$3,171,411$382,28938 claims
AmgenOtezla$801,967$152,25131 claims
Johnson & JohnsonTremfya$80,785$145,05711 claims
Incyte CorporationOpzelura$802,121$27,58514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →